Marks Gilbert Lynninsider trades

In SEC Form 4 filings, Marks Gilbert Lynn is listed as Director of AN2 Therapeutics, Inc. (ANTX). Marks Gilbert Lynn reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Oct 13.

Companies and roles

Company	Role	Transactions	Last filed
ANTXAN2 Therapeutics, Inc.	Director	1	Oct 13

Cluster buys

No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).

Form 4 historysince 2026-10-13

Company	Traded	Filed	Type	Shares	Price	Value	Owned after	10b5-1 plan	Filing
ANTXAN2 Therapeutics, Inc.	Oct 12	Oct 13	A	2,283	$0.00	$0	84,156	No	Form 4

Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.